Combination of TST001, Nivolumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

950

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

October 1, 2025

Study Completion Date

January 31, 2026

Conditions

Gastric CancerGastroesophageal-junction CancerAdvanced Cancer

Interventions

DRUG

TST001, CapOx or mFOLFOX6 and NIVO or (Substudy) TST001, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)

All medications administered intravenously

DRUG

Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)

All medications administered intravenously

All Listed Sponsors

lead

Suzhou Transcenta Therapeutics Co., Ltd.

INDUSTRY